Image Source: Pixabay

What has Wall Street been buzzing about this week? Here is a quick look at the top 5 Buy calls and the top 5 Sell calls made by Wall Street's best analysts during the trading week of Oct. 27-31, 2025. First, here are the top 5 Buy calls of the week.

1. Microsoft Upgraded to Buy at Guggenheim

Guggenheim upgraded Microsoft (MSFT) to Buy from Neutral with a $586 price target. The firm believes Microsoft, in addition to the other hyperscalers, is a beneficiary from the artificial intelligence "casualties."

Microsoft has a "near monopoly" in the productivity suite market with its Office product, and the company will continue to monetize AI offerings tied to that product suite, Guggenheim tells investors in a research note. The firm believes Windows is also positioned to outperform consensus estimates over the near- to medium-term, representing the company's "second monopoly."

2. Roblox Upgraded to Buy at Goldman Sachs 

Goldman Sachs upgraded Roblox (RBLX) to Buy from Neutral with a price target of $180, up from $155, following the Q3 earnings report. The company is seeing strength in bookings, revenue, and daily active user growth, and management is optimistic surrounding the long-term scaling of the platform, the firm tells investors in a research note. Goldman now sees upside the company's forecasts, saying Roblox is positioned for long-term compounding and higher margins.

3. DoorDash Reinstated With a Buy at Goldman Sachs 

Goldman Sachs reinstated coverage of DoorDash (DASH) with a Buy rating and a $315 price target. The firm incorporated Deliveroo into its estimates and assumes DoorDash will invest to drive accelerating growth for the unit. Goldman's channel checks continue to point toward strong operational momentum in the delivery space. It sees DoorDash as having a "positive 3:1 risk/reward skew."

4. Five Below Upgraded to Overweight at JPMorgan 

JPMorgan upgraded Five Below (FIVE) to Overweight from Neutral with a price target of $186, up from $154, ahead of the Q3 report. The firm sees the company's multi-year earnings growth hitting at least low double-digits, supported by high-single-digit unit growth expansion and low-single-digit comps. Five Below's recent initiatives to improve product, marketing, and store experience should support consist net same-store-sales growth, contends JPMorgan.

5. Warner Bros. Discovery Upgraded to Buy at Rothschild & Co Redburn 

Rothschild & Co Redburn upgraded Warner Bros. Discovery (WBD) to Buy from Neutral with a $28 price target. The company is up for sale and a $27-$30 takeout price seems reasonable, the firm tells investors in a research note. Rothschild estimates cost synergies of $2 billion if Paramount buys all of Warner Bros., and around $1.3 billion for suitors looking to acquire just the studio.

Next, here are the top 5 Sell calls of the week.

1. Berkshire Downgraded to Underperform at Keefe Bruyette 

Keefe Bruyette downgraded Berkshire Hathaway (BRK-A) to Underperform from Market Perform with a price target of $700,000, down from $735,000. The firm believes the peaking of Geico's underwriting margin, declining property catastrophe reinsurance rates, lower short-term interest rates, the tariff-related pressure on the rails, and the risk of fading alternative energy tax credits will drive the stock to underperform over the next 12 months. "Many things are moving in the wrong direction" for Berkshire, Keefe tells investors in a research note.

2. Harley-Davidson Downgraded to Underweight at Morgan Stanley 

Morgan Stanley downgraded Harley-Davidson (HOG) to Underweight from Equal Weight with a price target of $25, down from $27, which offers 10% downside potential. The firm says Harley sits at the bottom of its "leisure framework" due to its combination of low pricing power and weak secular trends.

These factors, combined with competitive pressures, are "overwhelming a cyclical recovery" for the motorcycle industry, Morgan Stanley adds. The firm lowered its estimates and believes consensus numbers will come down further.

3. Equinor Downgraded to Underweight at Barclays

Barclays downgraded Equinor (EQNR) to Underweight from Equal Weight with a price target of NOK 230, down from NOK 325. The firm upgraded Galp and downgraded Equinor on "diverging 2026 capital frameworks and operational trajectories." It sees Galp entering an upstream growth phase supported by a disciplined capex plan, and believes Equinor faces elevated execution risk in renewables alongside stretched distribution capacity.

4. MoonLake Immunotherapeutics Downgraded to Sell at Citi

Citi downgraded MoonLake Immunotherapeutics (MLTX) to Sell from Neutral with an unchanged price target of $5. The shares have rallied from the lows post the disappointing hidradenitis suppurativa, but Citi is still cautious on the approvability and commercial competitiveness for sonelokima. The firm also believes MoonLake has a financing overhang.

5. Piper Double Downgrades Organon to Underweight after CEO Resignation

Piper Sandler analyst David Amsellem downgraded Organon (OGN) to Underweight from Overweight with a price target of $5, down from $18, calling the investigation that uncovered Nexplanon-related channel stuffing that led to the resignation of CEO Kevin Ali an "egregious breakdown in internal controls."

The firm believes that it will likely take "quite some time" for the board and new senior leadership to build "any modicum of credibility," even if it becomes clear that there were no other instances of lapses in internal controls and no other instances of malfeasance, the analyst tells investors.

More By This Author: